Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 vaccine in patients with CLL. We evaluated humoral immune responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccin...

詳細記述

保存先:
書誌詳細
出版年:Blood
主要な著者: Herishanu, Yair, Avivi, Irit, Aharon, Anat, Shefer, Gabi, Levi, Shai, Bronstein, Yotam, Morales, Miguel, Ziv, Tomer, Shorer Arbel, Yamit, Scarfò, Lydia, Joffe, Erel, Perry, Chava, Ghia, Paolo
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2021
主題:
CLINICAL TRIALS AND OBSERVATIONS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8061088/
https://ncbi.nlm.nih.gov/pubmed/33861303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2021011568
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料